JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP6727210B2 (ja
JP2018505146A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (enExample) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (enExample)
EP (1) EP3236991B1 (enExample)
JP (1) JP6727210B2 (enExample)
KR (1) KR102427527B1 (enExample)
CN (1) CN107108709B (enExample)
AR (1) AR103246A1 (enExample)
AU (1) AU2015371056B2 (enExample)
DK (1) DK3236991T3 (enExample)
ES (1) ES2742503T3 (enExample)
HK (1) HK1246156B (enExample)
HR (1) HRP20191292T1 (enExample)
HU (1) HUE044783T2 (enExample)
IL (1) IL252438B (enExample)
MX (1) MX377044B (enExample)
MY (1) MY181181A (enExample)
PL (1) PL3236991T3 (enExample)
PT (1) PT3236991T (enExample)
RS (1) RS59154B1 (enExample)
RU (1) RU2729011C2 (enExample)
SA (1) SA517381673B1 (enExample)
SI (1) SI3236991T1 (enExample)
TW (2) TWI681966B (enExample)
WO (1) WO2016102562A1 (enExample)
ZA (1) ZA201703768B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
CA3074380C (en) 2017-09-04 2023-01-03 89Bio Ltd. Mutant fgf-21 peptide conjugates and uses thereof
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4337681A1 (en) 2021-05-11 2024-03-20 Cytoki Pharma ApS Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
AU2022341345A1 (en) * 2021-09-08 2024-03-28 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
KR102749341B1 (ko) 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
AU2023303873A1 (en) 2022-07-08 2025-01-02 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
WO2024199734A2 (en) 2023-03-30 2024-10-03 Novo Nordisk A/S Fusion compounds and uses thereof
AU2024272220A1 (en) * 2023-05-12 2025-10-16 Novo Nordisk A/S Long-acting growth hormone receptor antagonist and use thereof
AR133774A1 (es) 2023-09-11 2025-10-29 Novo Nordisk As Anticuerpos de dominio anti-il-6
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合fgf−21化合物
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
MX2007002616A (es) 2004-09-02 2007-05-16 Lilly Co Eli Muteinas de factor de crecimiento de fibroblasto 21.
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
ES2692495T3 (es) * 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー/エス Fgf21類似体および誘導体
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
CA2845357A1 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
AU2013311777B2 (en) * 2012-09-07 2018-02-01 Sanofi Fusion proteins for treating a metabolic syndrome
SG11201504815QA (en) * 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Similar Documents

Publication Publication Date Title
JP2018505146A5 (enExample)
RU2017125050A (ru) Производные fgf21 и их применения
JP2013532644A5 (enExample)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2012529463A5 (enExample)
JP2011526886A5 (enExample)
JP2016512425A5 (enExample)
JP2013543497A5 (enExample)
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
JP2017500289A5 (enExample)
JP2017502024A5 (enExample)
JP2016500682A5 (enExample)
JP2012506402A5 (enExample)
RU2017101436A (ru) Mic-1 слитные белки и их применение
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
JP2014224121A5 (enExample)
JP2020524675A5 (enExample)
JP2017081939A5 (enExample)
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
WO2012069836A3 (en) Biologically active complex and its preparation
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF PUMP DISEASE
WO2008138348A1 (en) Preparation of complexed lactalbumin
JP2016523241A5 (enExample)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.